Status:
COMPLETED
Testing the Efficacy of Different Dosages of Lercanidipine to Reduce Hypertensive Blood Pressure in Normal Weight and Obese Patients
Lead Sponsor:
UCB Pharma
Conditions:
Hypertension
Eligibility:
All Genders
18-75 years
Phase:
NA
Brief Summary
A double blind study to examine the safety and efficacy of different dosages of lercanidipine in normal weight and obese patients with hypertension
Eligibility Criteria
Inclusion
- Body Mass Index (BMI): 18.0 - 24.9 or 30.0 - 39.9 kg/m2 (extremes included);
- Essential hypertension I or II WHO:
- 140 mmHg ≤ BPs ≤ 179 mmHg and BPd ≤ 109 mmHg at the end of the placebo run-in phase;
Exclusion
- Secondary hypertension;
- Diabetes mellitus type 1, insulin dependent diabetes mellitus type 2, fasting blood glucose ≥ 160 mg/dl;
- Subjects keeping to a hypocaloric diet (except special diet for diabetics) to reduce body weight;
- History or presence of angioneurotic oedema;
- Subjects developing a hypertensive crisis during wash-out or placebo run-in period;
Key Trial Info
Start Date :
May 1 2004
Trial Type :
INTERVENTIONAL
End Date :
August 1 2005
Estimated Enrollment :
180 Patients enrolled
Trial Details
Trial ID
NCT00160498
Start Date
May 1 2004
End Date
August 1 2005
Last Update
March 10 2008
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.